In PACE, 80% of CP-CML patients were resistant to dasatinib or nilotinib, and 24% had the BCR::ABL1T315I resistance mutation [3]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.